CD274 and cancer: Patients who received ICB or another treatment combined with ICB displayed a significant decrease in PD-L1 expression, suggesting either an ongoing evolution, reprogramming of cancer cells to suppress the immune response [101], or the expansion of a minor ICB resistant subclone under the selective pressure of treatment.